Research

Internet searches can identify drug safety issues well ahead of public alerts

The authors base their findings on an analysis of the anonymised search logs of millions of US web users, who agreed to install a browser add-on and share their online searches with Microsoft throughout 2010. The researchers developed automated tools to analyse the queries of people who searched for information on the antidepressant (paroxetine) and a cholesterol lowering drug (pravastatin), using the search engines Google, Bing and Yahoo.

In 2010, it was not yet public knowledge that taking both these two drugs caused high blood sugar (hyperglycaemia), but the authors later extracted this information by mining the US drugs regulator's medicines side effect reporting system (AERS) and confirming the finding in a separate laboratory study.

In the web log study, the authors looked at whether people who had searched online for either one of the drugs separately, or for both of them, would also search with queries containing terms associated with the symptoms of high blood sugar.

In all, they analysed 82 million drug, symptom, and condition queries from among 6 million web users.

They found that online searches for information on prescription drugs was common, with more than one in 250 people looking up at least one of the 100 top selling drugs in the US, including paroxetine and pravastatin.

For people who searched online for both drugs during the 12 month period, queries were made on the same day in almost a third (29.61%) of searches, while four out of 10 were in the same week. Six out of 10 were made within the same month.

During the study period, those people who looked up both drugs online were almost twice as likely to search for terms associated with high blood sugar as were those who looked up the drugs separately.

One in 10 of those looking up both drugs did this, compared with around one in 20 of those looking up each drug separately. Just 0.3% of all users searched for one or more terms associated with high blood sugar over the 12 months.

These differences in search patterns were evident across the whole period of the study, and were not influenced by public information as the discovery of the interaction between this particular pair of drugs was only made in 2011.

Analysis of other 31 drug pair interactions associated with high blood sugar also indicated similar patterns, suggesting that the value of log analysis is not just confined to paroxetine and pravastatin.

"There is a potential public health benefit in listening to such signals, and integrating them with other sources of information," write the authors. "We see a potentially valuable signal, even though search logs are unstructured, not necessarily related to health, and can include any words entered by users," they add.

And they conclude: "We believe that patient search behaviour directly captures aspects of patients' concerns about sensed [symptoms] and can complement more traditional sources of data for pharmacovigilance [drug safety monitoring]."

Most Popular Now

New antibiotic Zavicefta approved i…

AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a ne...

Read more

Novo Nordisk and Aarhus University …

Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Unde...

Read more

AstraZeneca enters licensing agreem…

AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, ...

Read more

Novartis adds bispecific antibodies…

Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. Th...

Read more

Bristol-Myers Squibb and PsiOxus Th…

Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, to...

Read more

Bristol-Myers Squibb acquires Cormo…

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormo...

Read more

Sanofi Pasteur signs research agree…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Resear...

Read more

FDA advances Precision Medicine Ini…

In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a fle...

Read more

Laboratory drug trials could lead t…

A new drug with the potential to reverse or slow the development of asthma is being tested by researchers at The University of Queensland. Developed by international phar...

Read more

Merck and Pfizer initiate Phase III…

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of ave...

Read more

Merck commits €1.5 million to the G…

Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Gra...

Read more

Twisting and turning to target anti…

Researchers are getting closer to understanding how some natural antibiotics work so they can develop drugs that mimic them. A recent review commissioned by the British g...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016